Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02203903 · ClinicalTrials.gov registry record · Phase 1
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
A Phase 1 study of Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS, sponsored by Catherine Bollard.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT02203903: Recruiting Phase 1 study of Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS, sponsored by Catherine Bollard.
NCT02203903 is a Phase 1 study of Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS that is actively recruiting participants, run by Catherine Bollard. The registered enrollment target is 50 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02203903, a Phase 1 study of Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS, is actively recruiting participants, sponsored by Catherine Bollard.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.
Primary Outcome
Acute GVHD grades III-IV within 45 days of the last dose of TAA-T
Interventions
- BIOLOGICAL Tumor associated antigen lymphocytes (TAA-T)
Study Locations (2)
District of Columbia
- Childrens National Medical Center - Washington D.C.
Maryland
- Tania Jain, MD - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-01-01 |
| Est. Completion | 2027-06-28 |
| Phase | Phase 1 |
What NCT02203903 shows while recruiting
NCT02203903 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS appearing as the primary indexed condition, and to 1 intervention - of which Tumor associated antigen lymphocytes (TAA-T) is the first listed.
NCT02203903 reports a single indexed study location in District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT02203903 about?
NCT02203903 is a clinical study titled "Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies". This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.
What is the current status of trial NCT02203903?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2015-01-01. Estimated completion is 2027-06-28.
What conditions does trial NCT02203903 study?
This clinical trial studies the following conditions: Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS.
What interventions are being tested in trial NCT02203903?
The interventions under investigation include: Tumor associated antigen lymphocytes (TAA-T) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02203903?
This trial is sponsored by Catherine Bollard, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02203903 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02203903's enrollment target sits among peer trials
50 974th of 2000 higher than 984 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI